Research progress on novel antibody drug conjugates in cancer therapy
Yuning Li1,2, Jialin Su3,4, Shuhua Tan4
1Thoracic Medicine Department 1, Hunan Cancer Hospital, Changsha 410013. 1224284589@qq.com.
Abstract:
Traditional antibody drug conjugates (ADC) combine monoclonal antibodies with cytotoxic drugs to accurately strike cancer cells, but there are still many shortcomings in stability, targeting, efficacy, and safety. Novel ADC, such as bi-specific, site-specific, dual-payload, and pro-drug type ADC, can be optimized by simultaneously binding 2 different antigens or epitopes, selecting more stable linkers, coupling with specific amino acid sites of antibodies, carrying different drug payloads, and adopting prodrug strategies, while retaining the characteristics of traditional ADC. Significantly improving the stability, targeting, efficacy and safety of drugs can better meet the needs of clinical treatment. Novel ADC will play a more important role in cancer treatment in the future. Discussing the progress of novel ADC in cancer treatment and analyzing their advantages and challenges can provide theoretical support for the development of anti-cancer strategies and provide directions for drug research and development.
Insights
Novel antibody-drug conjugates (ADCs) offer improved stability, targeting, efficacy, and safety over traditional ADCs, paving the way for better cancer treatments.
Area of Science:
- Oncology
- Biotechnology
- Pharmacology
Background:
- Traditional antibody-drug conjugates (ADCs) have limitations in stability, targeting, efficacy, and safety.
- These shortcomings hinder optimal cancer cell destruction and increase off-target effects.
Purpose of the Study:
- To review advancements in novel antibody-drug conjugate (ADC) designs.
- To analyze the advantages and challenges of these new ADC strategies in cancer therapy.
Main Methods:
- Exploration of novel ADC designs including bi-specific, site-specific, dual-payload, and pro-drug types.
- Analysis of optimization strategies such as dual-antigen binding, stable linkers, site-specific conjugation, and prodrug approaches.
Main Results:
- Novel ADCs demonstrate enhanced stability, improved targeting precision, increased efficacy, and better safety profiles.
- These innovations address the limitations of traditional ADCs, offering superior clinical potential.
Conclusions:
- Novel ADCs represent a significant evolution in cancer treatment, overcoming traditional limitations.
- Further research and development in novel ADCs are crucial for advancing anti-cancer strategies and drug discovery.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:31Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...